A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
Peng Zhang, Elisabeth Narayanan, Qingbo Liu, Yaroslav Tsybovsky, Kristin L. Boswell, Shilei Ding, Zonghui Hu, Dean Follmann, Yin Lin, Huiyi Miao, Hana Schmeisser, Denise Rogers, Samantha Falcone, Sayda M. Elbashir, Vladimir Presnyak, Kapil Bahl, Madhu Prabhakaran, Xuejun Chen, Edward K. Sarfo, David R. Ambrozak, Rajeev Gautam, M A Martin, Joanna Swerczek, Richard Herbert, Deborah Weiss, Johnathan Misamore, Giuseppe Ciaramella, Sunny Himansu, Guillaume B. E. Stewart-Jones, Adrian B. McDermott, Richard A. Koup, John R. Mascola, Andrés Finzi, Andrea Carfı́, Anthony S. Fauci, Paolo Lusso
Topics & Concepts
VirologyHeterologousSimian immunodeficiency virusAntibodyBiologyNeutralizing antibodyVirusNeutralizationGp41HIV vaccineAIDS VaccinesGlycanVaccinationImmunologyGlycoproteinVaccine trialGeneEpitopeMolecular biologyGeneticsHIV Research and TreatmentImmune Cell Function and InteractionRNA Interference and Gene Delivery